BioToxTech Co

BioToxTech Co Gross Margin

The Gross Margin of BioToxTech Co (086040.KQ) as of Nov 19, 2026 is 12.51 %. In the previous year, Gross Margin was 6.19 % — a change of 102.16% (higher).

Gross Margin

12.51 %

YoY

102.16%

Last updated:

Gross Margin of BioToxTech Co is 2025 12.51 % . Gross Margin of BioToxTech Co was 2024 6.19 % . It decreases by 102.16% higher compared to the previous year.

For BioToxTech Co, the gross margin of 12.5% is down versus 37.3% a few years ago.

The BioToxTech Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
28.16 KRW
Jan 1, 2019
20.77 KRW
Jan 1, 2020
30.52 KRW
Jan 1, 2021
37.34 KRW
Jan 1, 2022
38.68 KRW
Jan 1, 2023
17.09 KRW
Jan 1, 2024
6.19 KRW
Jan 1, 2025
12.51 KRW
The BioToxTech Co Gross Margin history
YEARGross MarginYoY
12.51 %+102.16%
6.19 %-63.81%
17.09 %-55.80%
38.68 %+3.58%
37.34 %+22.34%
30.52 %+46.97%
20.77 %-26.25%
28.16 %-21.07%
35.68 %+7.69%
33.13 %+81.21%
18.28 %+69.09%
10.81 %+3,308.05%
0.32 %-6.49%
0.34 %+59.29%
0.21 %-30.06%
0.30 %-1.99%
0.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Gross Margin of BioToxTech Co is 12.51 % in 2025.

Gross Margin of BioToxTech Co changed from 6.19 % to 12.51 %, representing a 102.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's BioToxTech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — BioToxTech Co

All Key Metrics — BioToxTech Co